Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus ADZENYS ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus ADZENYS ER.
ADDERALL 5 vs ADZENYS ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Category C
Category C
CNS Stimulant
CNS Stimulant